Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Sana Biotechnology, Inc. (SANA)

Sana Biotechnology Q3 net income of $20.4 million driven by non-cash gain; cash $121.7 million

Mixed Impact 3 of 5 earnings Written later

Sana Biotechnology reported third-quarter 2026 GAAP net income of $20.4 million, or $0.07 per share, compared with a net loss of $42.2 million, or $0.16 per share, a year earlier. The swing was mainly due to a $63.4 million non-cash gain from changes in the fair value of success payment and contingent consideration liabilities, while non-GAAP net loss widened to $43.0 million from $39.0 million, and cash, equivalents and marketable securities fell to $121.7 million with runway expected into mid-2027.

Key points

  • Q3 2026 GAAP net income was $20.4 million ($0.07 per share), versus a $42.2 million net loss in Q3 2025, including a $63.4 million non-cash gain.
  • Q3 2026 non-GAAP net loss was $43.0 million ($0.14 per share), compared with $39.0 million ($0.15 per share) in Q3 2025.
  • Cash, cash equivalents and marketable securities were $121.7 million at September 30, 2026, down from $138.4 million at December 31, 2025; cash used in operations was $108.9 million for the nine months.
  • Q3 2026 research and development expenses were $33.9 million, up from $30.1 million, and the company expects cash runway into mid-2027.

The filing

CompanySana Biotechnology, Inc. (SANA)
Form8-K, current report
Filed with the SECNov 5, 2026, 4:08 PM ET
Accession number0001193125-26-449791

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.